TY - JOUR
T1 - Homologous recombination deficiency in triple negative breast cancer
AU - Belli, Carmen
AU - Duso, Bruno Achutti
AU - Ferraro, Emanuela
AU - Curigliano, Giuseppe
N1 - Publisher Copyright:
© 2019
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.
AB - Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.
KW - BRCA mutations
KW - Homologous recombination deficiency
KW - PARP inhibitors
KW - Platinum agent
KW - Triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85061966839&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2019.02.007
DO - 10.1016/j.breast.2019.02.007
M3 - Review article
C2 - 30818144
AN - SCOPUS:85061966839
SN - 0960-9776
VL - 45
SP - 15
EP - 21
JO - Breast
JF - Breast
ER -